Table 4.

Recent studies evaluating the use of adalimumab in sarcoid-associated uveitis

Study	Design	Etiology of uveitis	Outcome
Suhler et al77	Multicenter, open-label, prospective	31 patients, 6/31 (19.3%) sarcoidosis	6/6 clinical responders at 10 weeks, 3/6 secondary failure at 50 weeks
Taylor et al71	Double-blind, placebo-controlled, multinational, Phase III study	217 patients Sarcoidosis: 8/107 (7%) placebo group, 10/110 (9%) adalimumab group	Adalimumab found to be associated with a lower risk of uveitic flare or visual impairment and with more adverse events and serious adverse events than placebo
Airody et al72	Double-blind, placebo-controlled, multinational, Phase III study	226 patients Sarcoidosis: 14/111 (13%) placebo group, 18/115 (16%) adalimumab group	Adalimumab significantly reduced the risk of uveitic flare or loss of visual acuity in patients with inactive, uninfectious intermediate, posterior, or panuveitis
Riancho-Zarrabeitia et al78	Open-label, multicenter, retrospective study	17 patients with sarcoid uveitis (10 received adalimumab, 7 infliximab)	Anti-TNFα therapy effective in sarcoid uveitis patients refractory to conventional immunosuppressive therapy; infliximab and adalimumab allowed substantial reduction in prednisone dose, despite having failed standard therapy
Mercier et al79	Monocentric observational retrospective study	21 patients Sarcoidosis: 2/21 (9.5%)	Anti-TNFα therapy effective on macular edema with a statistically significant reduction of MMT at M3, M6, and M12; regarding sarcoidosis, difficult to interpret, because only two patients were involved
Erckens et al80	Prospective case series	26 sarcoidosis patients with refractory posterior uveitis	Intraocular inflammatory signs showed improvement in 22 patients (85%) and stabilization in four patients (15%); at 12 months, no recurrences were reported in those successfully treated